BioGeneration Ventures

AdBio partners (formerly Advent France Biotechnology) is a venture capital firm investing in early stage life sciences companies in Europe. AdBio partners’ unique strategy combines early-stage investments in promising startups and strong entrepreneurial support to enable and strengthen the company’s growth. As an early-stage investor, we act as a catalyst to create companies based on innovations coming from academic research. We have established relationships with leading research institutions and technology transfer offices in Europe and benefit from the support of strong network of scientific, clinical, industry and financial partners. The operational team is managed by Alain Huriez, MD, Chairman and Managing Partner, and Geoffroy de Ribains, Managing Partner. The team includes seasoned investment professionals with long-standing track records in entrepreneurial ventures, combined with strong scientific, medical and operational expertise.

Our Ventures team supports the launch of startups based on University of Michigan technologies and research discoveries. We provide a full suite of resources, services and funding to help you launch sustainable, impactful world changing startups. The Ventures team will engage with you from day one to establish clear and executable commercialization, business formation and funding strategies. As your startup project begins to take form we can provide grant funding and investment capital, as well as business know-how, talent resources and connections to a nationwide network of investors. Whether it is helping you find the perfect team member, investment partner or connecting you with service providers, we have you covered.

We’re a small team of investors, entrepreneurs, operators, clinicians, scientists and technologists, supported by our Board of healthcare and life sciences leaders and an Investment Committee of experienced venture investors and innovators. Together the partners represent one of the largest teaching hospital systems in the UK and Europe, serving a diverse local population. Their vision is to support world-leading healthcare ecosystem that drives new frontiers in modern medicine with synergistic integration of healthcare, academia, innovation and private capital.

SCI Ventures is a novel, evergreen fund created to catalyze innovative cures for paralysis. Backed by the leading foundations for spinal cord injury in the US and Europe, and advised by world-class neuroscientists, we invest in early-stage companies developing cure-oriented therapies for spinal cord injury and other related markets. We invest globally in companies with the greatest potential to impact our mission, typically at the Seed and Series A stages. We follow a venture philanthropy model, inspired by successful initiatives in other disease areas, to catalyze an investment market aimed at reversing paralysis. We focus on investing in companies advancing cures for paralysis-related challenges, prioritizing both long-term neural pathway restoration and immediate clinical impact. Our investments are guided by community priorities and scientific rigor, leveraging our team's expertise and the support of research foundations. A new wave of innovation For the first time, the combination of breakthroughs in biology, engineering and computing make a cure to paralysis a real possibility. An evergreen fund that redeploys 100% of its returns Venture philanthropy has been adopted by a number of disease- focused organisations, including JDRF’s T1D Fund and the Cystic Fibrosis Foundation, to deploy their own capital to produce a tangible impact and to attract the traditional life-science venture capital industry to their cause. SCI Ventures is making investments with the intent of generating a financial return. All returns will be recycled and reinvested within the fund to take more targeted shots at the goal of curing paralysis. All initial operating costs of SCI Ventures are being met by the Christopher and Dana Reeve Foundation, allowing all donated capital to be invested in cutting-edge, early-stage companies. Investment strategy Catalyzing an investment market to address spinal cord repair. Recent advances in science and technology have made recovery from paralysis a real possibility. We target near-term functional improvement, while also backing the ultimate goal of biological repair of the spinal cord. Our strategy is guided by the priorities of those living with a spinal cord injury. We focus on curative therapies for motor and sensory deficits and leave the important work of care and adaptation to others. SCI Ventures is uniquely positioned to de-risk assets for a broad range of adjacent neurological conditions. We invest in technologies targeted at SCI. There are many similarities between SCI and other conditions including stroke, neurodegenerative diseases or neural circuit disorders such as epilepsy or pain. The technologies we back have the potential to yield high impact beyond the SCI community. We use strict criteria to assess a company’s investment impact, focusing on prospective financial return. We aim to make an impact, by identifying the most innovative technologies and supporting at an early stage the most entrepreneurial management teams, regardless of where they are in the world. We assess each company for its scientific maturity and potential for clinical impact.

The journey from discovery to medical breakthrough demands imagination, speed, and focus. At Mission BioCapital, we provide early-stage capital to the next generation of awesome life science entrepreneurs and the platform where they can realize their visions. This approach has revolutionized the way life science start-ups progress from idea to key data through a model that champions collaboration at the center of everything we do. Our team has a deep-rooted commitment to empowering exceptional life science entrepreneurs from all walks of life. From your first experiment in our shared lab space through to the clinic, we want to be your partner in accelerating development of scientific solutions – faster, focused and more efficiently – to individuals and communities in most need. We’re there, from idea to exit. We are scientists, investors, founders, and serial entrepreneurs. Our team has a long history together, investing in, launching, and building dozens of early-stage life science companies. Making Transformational Investments. Founded in 2009, we are now investing out of our fifth fund. Since our inception, we have invested in early-stage life science companies following the same core principles: Mentorship and Collaboration – within our team and with founders Innovation and Creativity – in how we structure our investments and find solutions to problems; we are entrepreneurs too! Respect and Support – for the founders we work with

Cambrian Biopharma, a multi-asset longevity biotech, is building the medicines that will redefine healthcare in the 21st century – therapeutics to lengthen healthspan, the period of life spent in good health. By partnering with leading academic institutions and biotech entrepreneurs all over the world, we are advancing a diversified pipeline of novel therapeutics, each targeting a biological driver of aging. Our approach is to develop interventions that treat specific diseases first, then deploy them as preventative medicines to improve overall quality of life as we age. Cambrian is a Distributed Development Company (or DisCo) which combines the advantages of a venture capital firm and a big pharmaceutical company, with the nimbleness of a biotech startup. Cambrian’s sourcing and development engine allows us to identify promising science, deploy capital and teams of drug development experts, and provide stewardship to advance new medicines. By leveraging established expertise and repeatable functional models, we achieve vast efficiencies in execution speed and resource utilization. To date, we have 14 novel therapeutics in development, and having closed a Series C financing round in October 2021 which raised $100 million, we plan to expand the number of programs. Further, we expect to initiate clinical trials for three programs in the next 18 months.